Oncolytics Biotech Inc
ONCY
查看详细走势图
1.010USD
0.000
收盘 12/19, 16:00（美东）报价延迟15分钟
104.67M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
0.00%
5天
+1.70%
1月
+1.00%
6月
+46.36%
今年开始到现在
+10.53%
1年
+21.54%
查看详细走势图
TradingKey Oncolytics Biotech Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Oncolytics Biotech Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名178/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.75。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Oncolytics Biotech Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
6
位分析师
买入
评级
5.750
目标均价
+508.66%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Oncolytics Biotech Inc亮点
亮点风险
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值合理
公司最新PE估值-3.53，处于3年历史合理位
机构减仓
最新机构持股1.43M股，环比减少75.11%
活跃度降低
近期活跃度降低，过去20天平均换手率0.11
Oncolytics Biotech Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Oncolytics Biotech Inc简介
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
公司代码ONCY
公司Oncolytics Biotech Inc
CEOKelly (Jared Ryan)
网址https://www.oncolyticsbiotech.com/
常见问题
Oncolytics Biotech Inc(ONCY)的当前股价是多少？
Oncolytics Biotech Inc(ONCY)的当前股价是 1.010。
Oncolytics Biotech Inc的股票代码是什么？
Oncolytics Biotech Inc的股票代码是ONCY。
Oncolytics Biotech Inc股票的52周最高点是多少？
Oncolytics Biotech Inc股票的52周最高点是1.510。
Oncolytics Biotech Inc股票的52周最低点是多少？
Oncolytics Biotech Inc股票的52周最低点是0.326。
Oncolytics Biotech Inc的市值是多少？
Oncolytics Biotech Inc的市值是104.67M。
Oncolytics Biotech Inc的净利润是多少？
Oncolytics Biotech Inc的净利润为-31.71M。
现在Oncolytics Biotech Inc(ONCY)的股票是买入、持有还是卖出？
根据分析师评级，Oncolytics Biotech Inc(ONCY)的总体评级为买入，目标价格为5.750。
Oncolytics Biotech Inc(ONCY)股票的每股收益（EPS TTM）是多少
Oncolytics Biotech Inc(ONCY)股票的每股收益（EPS TTM）是-0.286。
相关品种
